Status:
COMPLETED
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Cancer Survivor
Eligibility:
FEMALE
65-120 years
Phase:
NA
Brief Summary
RATIONALE: Aerobic exercise, resistance exercise, and flexibility and relaxation training may reduce fatigue and improve the health and quality of life of breast cancer survivors. It is not yet known ...
Detailed Description
OBJECTIVES: Primary: * Compare the effects of aerobic exercise vs flexibility and relaxation training (control) on fatigue, aerobic capacity, functioning, and health outcomes in inactive older femal...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of breast cancer
- Stage 0-III disease
- Completed chemotherapy or radiotherapy \> 2 years ago
- Is not a regular participant in moderate aerobic exercise (i.e., jogging, swimming) or moderate resistance exercise (\> 3 times/week for ≥ 30 minutes/session) OR in vigorous aerobic or resistance exercise (\> 3 times/week for ≥ 20 minutes/session)
- No stage IV breast cancer
- Hormone receptor status not specified
- PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Has obtained medical clearance to participate in study exercise programs
- No cognitive difficulties that would preclude answering the survey questions, participating in the performance tests, or giving informed consent
- No medical condition or movement or neurological disorder that would contraindicate participation in moderate intensity exercise training, as determined by physician clearance and the Principal Investigator
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent medication that would contraindicate participation in moderate intensity exercise training, as determined by physician clearance and the Principal Investigator
- Concurrent hormonal therapy (e.g., selective estrogen receptor modulator (SERM) or aromatase inhibitor) for breast cancer allowed
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00662103
Start Date
March 1 2008
End Date
June 1 2010
Last Update
October 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States, 97239-3098